granzyme B Inhibitors

Granzyme B inhibitors represent a class of compounds designed to target and modulate the activity of the serine protease enzyme known as granzyme B. Granzymes are a group of enzymes primarily found in cytotoxic immune cells, such as cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells. Granzyme B, in particular, plays a crucial role in the immune system's defense against infected or cancerous cells. When these immune cells recognize a target cell, they release granzyme B into the target cell, initiating apoptosis (programmed cell death). Granzyme B cleaves specific substrates within the target cell, leading to its demise. While this is a vital process for immune defense, it can be overly aggressive in certain situations, causing tissue damage and contributing to autoimmune diseases. Granzyme B inhibitors have been developed to regulate or attenuate this enzymatic activity. The development of granzyme B inhibitors involves the design and synthesis of molecules that can specifically bind to granzyme B, inhibiting its proteolytic activity. These inhibitors typically work by targeting the active site of granzyme B, preventing it from cleaving its substrates efficiently. Various chemical structures have been explored in the search for effective granzyme B inhibitors, including small molecules, peptides, and antibodies. The goal is to create compounds that can selectively inhibit granzyme B while sparing other crucial cellular processes. These inhibitors have garnered interest for their role in studying the underlying mechanisms of immune function and cell death pathways, shedding light on fundamental aspects of immunology and cell biology.